Boston Scientific Completes Acquisition of Sadra Medical
NATICK, Mass., Jan. 4, 2011 - Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of Sadra Medical, Inc. of Los Gatos, California. The transaction follows the definitive merger agreement announced on November 19, 2010. Under the terms of the agreement, Boston Scientific paid $193 million to acquire the remaining 86 percent of Sadra Medical's equity not already owned by Boston Scientific. Additional payments of up to $193 million are contingent upon achievement of specified regulatory and revenue-based criteria through 2016. The Company expects the acquisition to be approximately one to two cents dilutive to GAAP and adjusted earnings per share in 2011, 2012 and 2013, and accretive thereafter.
Sadra Medical is developing the first fully repositionable device for percutaneous aortic valve replacement to treat patients with severe aortic stenosis. The company recently completed a series of European feasibility studies for its Lotus(TM) Valve System, which consists of a stent-mounted tissue valve prosthesis and catheter delivery system for guidance and placement of the valve. The low-profile delivery system and introducer sheath are designed to enable accurate positioning, repositioning and retrieval at any time prior to release of the aortic valve implant.
"We are pleased to complete the acquisition of Sadra Medical, and we look forward to leveraging our clinical expertise and existing sales channels in the fast-growing area of structural heart therapy," said Ray Elliott, President and Chief Executive Officer of Boston Scientific. "Structural heart therapy is one of our Priority Growth Initiatives, and this acquisition marks another step toward realigning our portfolio through the execution of these initiatives."
About Aortic Valve Disease
Aortic valve disease results in dysfunction of the aortic valve, one of the four valves that control the flow of blood in and out of the heart. Aortic valve stenosis is the process of thickening and stiffening in the valve, which can result in an abnormal narrowing of the aortic valve opening and reduction in blood flow. Aortic stenosis is a common problem affecting approximately 2 percent of people over age 65 and 4 percent of people over age 85. The current worldwide market for percutaneous aortic valve replacement is estimated at $400 million with projections to grow to $2 billion by 2016.
About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
CONTACT:
Paul Donovan
508-650-8541 (office)
508-667-5165 (mobile)
Media Relations
Boston Scientific Corporation
Larry Neumann
508-650-8696 (office)
Investor Relations
Boston Scientific Corporation
Sean Wirtjes
508-652-5305 (office)
Investor Relations
Boston Scientific Corporation
SOURCE Boston Scientific Corporation
Web Site: www.bostonscientific.com
